MedPath

Analysis of Cell-free DNA (cfDNA) During Periodontitis

Completed
Conditions
Periodontal Diseases
Cardiovascular Diseases
Interventions
Other: Clinical Attachment level
Registration Number
NCT05590780
Lead Sponsor
University of Catania
Brief Summary

The purpose of this study was to examine the association between circulating cfDNA concentration and CVD risk in patients with periodontitis, CVD, and periodontitis plus CVD. In addition, the secondary objective was to identify, among other confounders, the impact of periodontitis and cardiovascular disease as potential significant predictors of circulating cfDNA levels in the enrolled population.

Detailed Description

Recent emerging evidence has shown that circulating cell-free (cf) DNA are involved in in several epigenetic processes linked with periodontitis, coronary stenosis and systemic inflammation. The present study was aimed at assessing the impact of periodontitis on circulating cfDNA levels and evaluating possible confounders that influenced this association. Healthy controls (n=30) and subjects with CVD (n=31), periodontitis (n=31) and periodontitis+CVD (n=30) were enrolled. All subjects underwent regular periodontal examination and blood sampling. The analysis of the plasma cfDNA concentrations was performed using a dsDNA Assay Kit.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
122
Inclusion Criteria
  • Presence of at least 15 teeth

  • CP with a minimum of 40% of sites with a clinical attachment level (CAL)

    ≥2mm and probing depth (PD) ≥4mm;

  • Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs

  • Presence of ≥40% sites with bleeding on probing (BOP)

Exclusion Criteria
  • Intake of contraceptives
  • Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study
  • Status of pregnancy or lactation
  • Previous history of excessive drinking
  • Allergy to local anaesthetic
  • Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
ControlClinical Attachment levelEvaluation of plasma cfDNA levels
PeriodontitisClinical Attachment levelEvaluation of plasma cfDNA levels
Cardiovascular diseaseClinical Attachment levelEvaluation of plasma cfDNA levels
Periodontitis + cardiovascular diseaseClinical Attachment levelEvaluation of plasma cfDNA levels
Primary Outcome Measures
NameTimeMethod
Clinical attachment level lossbaseline changes

Evaluation of changes (in millimeters) of Clinical attachment level loss

circulating cell-free DNAbaseline changes

Evaluation of changes (in millimeters) of plasma circulating cell-free DNA

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Catania

🇮🇹

Catania, CT, Italy

© Copyright 2025. All Rights Reserved by MedPath